scispace - formally typeset
Open AccessJournal ArticleDOI

Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium

Reads0
Chats0
TLDR
Results from the pooled analyses provide little evidence for an increased risk of lung cancer among habitual or long‐term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.
Abstract
To investigate the association between cannabis smoking and lung cancer risk, data on 2,159 lung cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Cancer Consortium. Study-specific associations between cannabis smoking and lung cancer were estimated using unconditional logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66-1.38). Compared to nonhabitual or never users, the summary OR was 0.88 (95%CI: 0.63-1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94 (95%CI: 0.67-1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75-4.00) and 1.74 (95%CI: 0.85-3.55), respectively. However, no association was found for the squamous cell carcinoma based on small numbers. Weak associations between cannabis smoking and lung cancer were observed in never tobacco smokers. Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and lung cancer, but precision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of lung cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Opportunities for cannabis in supportive care in cancer.

TL;DR: There is a reasonable amount of evidence to consider cannabis for nausea and vomiting, loss of appetite, and pain as a supplement to first-line treatments, and promising evidence to treat chemotherapy-induced peripheral neuropathy, gastrointestinal distress, and sleep disorders, but the literature is thus far too limited to recommend cannabis for these symptoms.
Journal ArticleDOI

Vaping and lung cancer - A review of current data and recommendations.

TL;DR: In this article, the authors performed a literature review of current and historical publications on lung cancer oncogenesis, vaping device/e-liquid contents and daughter products, molecular oncogenic mechanisms and the fundamental, potentially oncogeneic, effects of electronic cigarette smoke and e-liquid products.
Journal ArticleDOI

Cannabis Use, Lung Cancer, and Related Issues.

TL;DR: Cannabidiol and the delta‐9‐tetrahydrocabinol strength and use are controlled and documented and cannabis appears to have an emerging therapeutic role, especially in chronic disease and as an adjunct to cancer treatment.
Journal ArticleDOI

Scientific Advances in Thoracic Oncology 2016

Ross A. Soo, +42 more
TL;DR: Experts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for NSCLC, SCLC and mesothelioma.
Journal ArticleDOI

Medical cannabis: A forward vision for the clinician.

TL;DR: Cannabinoids may hold promise for relief of symptoms in a vast array of conditions, but with many questions as yet unanswered, Rigorous study is needed to examine the true evidence for benefits and risks for various conditions and in various patient populations.
References
More filters
Journal ArticleDOI

Measuring inconsistency in meta-analyses

TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Book

Cancer Epidemiology and Prevention

TL;DR: This is an account of cancer epidemiology has been expanded and contains new material on cancer biology, molecular epidemiology, preventive strategies and specific types and sites of cancer.

European Monitoring Centre for Drugs and Drug Addiction

Matt Anderson
TL;DR: The EMCDDA Programme 2, 'Analysis of responses', set out to identify how social reintegration is understood in each Member State and to map the availability of social reIntegration facilities in Member States according to these national perceptions.
Related Papers (5)